Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab

Ruwaard, J.; l’Ami, M.; Marsman, A.; Kneepkens, E.; Denderen, J.C. van; Horst‐Bruinsma, Irene E. van der; Nurmohamed, Michael T.; Wolbink, Gertjan

doi:10.1080/03009742.2017.1330419

Cited by 11 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Axial spondyloarthritis (axSpA), a chronic inflammatory disease leading to vertebral and sacroiliac fusion, is characterized by lower back pain and back stiffness in the morning 1–3 . Even though there is still no cure for axSpA patients, the application of tumor necrosis factor‐α (TNF‐α) inhibitor in the treatment of axSpA ameliorates the disease status, including controlling the inflammation, decreasing the disease activity, and improving the health‐related quality of life 4–6 . However, the annual cost of TNF inhibitor is high; in addition, a certain proportion of axSpA patients stop the TNF inhibitor therapy because of the lack of efficacy and the presence of adverse events 7–9 .…”

Section: Introductionmentioning

confidence: 99%

Measurement of pre‐treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients

Peng¹,

Chen

Wen

et al. 2022

Int J of Rheum Dis

View full text Add to dashboard Cite

Aim To evaluate the correlation of inflammatory cytokines with the treatment response to tumor necrosis factor inhibitor (TNFi) in axial spondyloarthritis (axSpA) patients. Methods This study enrolled 86 axSpA patients and 20 healthy controls (HCs). Inflammatory cytokines including tumor necrosis factor‐α (TNF‐α), interleukin (IL)‐1β, IL‐6, IL‐12, IL‐17A, IL‐21, IL‐23, and IL‐32 were determined in serum samples of axSpA patients before treatment and in HCs after enrollment. All patients received 40 mg adalimumab every 2 weeks for 12 weeks; meanwhile, ASAS40 (40 criteria of the Assessment by the SpondyloArthritis International Society) response rates were evaluated at weeks 2, 4, 8, and 12. Results Most inflammatory cytokines were elevated in axSpA patients compared with HCs (all P < 0.05) except for IL‐32 (P = 0.101). In axSpA patients, ASAS40 response rates were 0%, 19.5%, 34.5%, 47.1%, and 56.3% at weeks 0, 2, 4, 8, and 12, respectively. Baseline [interquartile range] IL‐6 (47.3 [32.5‐53.4] pg/mL vs 31.7 [23.0‐50.9] pg/mL, P = 0.005) and IL‐17A (127.9 [90.7‐149.5] pg/mL vs 96.6 [56.1‐112.6] pg/mL, P < 0.001) were higher in axSpA patients with ASAS40 response compared with those without ASAS40 response, while baseline TNF‐α, IL‐1β, IL‐12, IL‐21, IL‐23, and IL‐32 were not different between them (all P > 0.050). Multivariate logistic regression analysis disclosed that baseline IL‐17A (P = 0.037), C‐reactive protein (P = 0.012), and history of TNF inhibitor (P = 0.029) were independently associated with ASAS40 response. Furthermore, baseline IL‐17A, C‐reactive protein, history of TNFi, and their combination had an acceptable to good ability for predicting ASAS40 response. Conclusion Measurement of pre‐treatment inflammatory cytokine levels is valuable for predicting treatment efficacy of TNFi in axSpA patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Measurement of pre‐treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients

Peng¹,

Chen

Wen

et al. 2022

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…The continuous development and progression of ankylosing spondylitis will eventually lead to spinal fusion and ligamentous ossifications, imposing heavy economic and psychological burdens on patients and their families [3]. In spite of the efforts made in the treatment of ankylosing spondylitis, outcomes are still poor in many patients [4,5]. Ankylosing spondylitis patients are also at high risk of other diseases, such as cardiovascular disease [6,7].…”

Section: Introductionmentioning

confidence: 99%

Overexpression of Long Noncoding RNAs (lncRNA) NF-κβ-Interacting Long Noncoding RNA (NKILA) in Ankylosing Spondylitis is Correlated with Transforming Growth Factor β1 (TGF-β1), Active Disease and Predicts Length of Treatment

Gai

2019

Med Sci Monit

View full text Add to dashboard Cite

Background Long noncoding RNAs (lncRNA) NF-κβ-interacting long noncoding RNA (NKILA) is downregulated in various types of cancers, while its involvement in other diseases is unknown. In the present study we found that plasma lncRNA NKILA was expressed at higher levels in active ankylosing spondylitis patients than in healthy controls. Material/Methods According to Youden’s index, active disease patients were divided into high and low lncRNA NKILA groups. Results Patients in the high lncRNA NKILA level group had significantly longer length of treatment and higher re-hospitalization rate at 3 years after discharge. Plasma levels of TGF-β1 were also higher in active ankylosing spondylitis patients than in healthy controls. Levels of plasma lncRNA NKILA and TGF-β1 were significantly and positively correlated in ankylosing spondylitis patients but not in healthy controls. Conclusions Overexpression of lncRNA NKILA in ankylosing spondylitis is correlated with active disease and predicts length of treatment. LncRNA NKILA may participate in ankylosing spondylitis through the interaction with TGF-β1, which is a key player in this disease.

show abstract

“…We performed additional subgroup analyses to further compare the clinical effect among different TNF-a inhibitors. A previous study indicated that etanercept and adalimumab treatment led to similar ASDAS-CRP improvement in patients with AS (16). In this study, the ASAS remission rates and HIMRISS were simultaneously compared between etanercept/ infliximab and adalimumab at follow-up time points.…”

Section: Discussionmentioning

confidence: 91%

“…Increasing evidence indicates that early detection and diagnosis of hip inflammation are beneficial to active treatment, which is important to improve hip function and general prognosis of SpA ( 14 ). Tumor necrosis factor (TNF)-α inhibitors are a prompt and robust treatment to improve the signs and symptoms of SpA as well as function and spinal mobility ( 15 , 16 ). In recent clinical studies, TNF-α inhibitors, including etanercept, adalimumab, and infliximab, were shown to be effective for patients with SpA patients with hip involvement in clinical and imaging assessments ( 1 ).…”

Section: Introductionmentioning

confidence: 99%

The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

et al. 2021

View full text Add to dashboard Cite

ObjectivesHip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-α inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation.MethodsA total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-α inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS).ResultsThe clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p < 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-α inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-α inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 ± 10.37 vs. 20.59 ± 9.41, p < 0.001); the control group only had slight improvement (p < 0.05).ConclusionsTNF-α inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-α in SpA patients with hip involvement to help guide targeted treatment.

show abstract

Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab

Cited by 11 publications

References 30 publications

Measurement of pre‐treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients

Measurement of pre‐treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients

Overexpression of Long Noncoding RNAs (lncRNA) NF-κβ-Interacting Long Noncoding RNA (NKILA) in Ankylosing Spondylitis is Correlated with Transforming Growth Factor β1 (TGF-β1), Active Disease and Predicts Length of Treatment

The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study

Contact Info

Product

Resources

About